MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-27-2024
Ampio Pharmaceuticals Total Non Current Liabilities 2011-2026 | AMPE
Annual Total Non Current Liabilities Ampio Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 3.53 M | 3.27 M | 7.41 M | 45.6 M | 4.83 M | 6.98 M | 1.13 M | 331 K | 381 K | 431 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 45.6 M | 331 K | 7.39 M |
Quarterly Total Non Current Liabilities Ampio Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.98 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.98 M | 6.98 M | 6.98 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apellis Pharmaceuticals
APLS
|
289 M | $ 20.15 | -2.68 % | $ 2.54 B |  USA |
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
2.21 M | $ 0.82 | -3.48 % | $ 4.47 M |  China |
 |
Axsome Therapeutics
AXSM
|
48.9 M | $ 163.7 | -1.61 % | $ 8.14 B | USA |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M |  France |
 |
AbCellera Biologics
ABCL
|
326 M | $ 3.72 | -2.75 % | $ 1.11 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Corvus Pharmaceuticals
CRVS
|
2.31 M | $ 17.75 | -0.79 % | $ 852 M | USA |
 |
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Certara
CERT
|
482 M | $ 7.16 | 1.49 % | $ 1.15 B | USA |
 |
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
4.86 M | $ 25.91 | -3.56 % | $ 694 M | USA |
 |
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
28.2 M | $ 0.99 | -3.28 % | $ 72.7 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
648 K | $ 24.0 | 0.5 % | $ 2.93 B | USA |
 |
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
264 M | $ 3.19 | -4.64 % | $ 1.14 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
157 M | $ 28.78 | -1.44 % | $ 1.67 B | USA |
 |
Champions Oncology
CSBR
|
1 M | $ 6.0 | -1.15 % | $ 82 M | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Завод ДИОД
DIOD
|
89.5 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
13.2 M | - | - | - | Russia |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |
 |
Cellectis S.A.
CLLS
|
109 M | $ 3.67 | -3.42 % | $ 116 M | France |
 |
Alector
ALEC
|
165 M | $ 2.11 | -4.75 % | $ 217 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
110 M | $ 15.68 | -2.4 % | $ 779 M | Britain |
 |
Allena Pharmaceuticals
ALNA
|
10.2 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
5.33 M | $ 4.17 | 0.24 % | $ 296 M | USA |
 |
Teligent, Inc.
TLGT
|
142 M | - | -13.85 % | $ 16.1 M | USA |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
1.38 M | - | - | $ 2.91 B | USA |
 |
Amarin Corporation plc
AMRN
|
31.7 M | $ 14.27 | 2.44 % | $ 5.92 B |  Irlanda |